Cantor Fitzgerald Has Negative View of CAPR FY2025 Earnings

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for shares of Capricor Therapeutics in a note issued to investors on Monday, July 14th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biotechnology company will post earnings of ($1.98) per share for the year, down from their previous forecast of $1.71. Cantor Fitzgerald has a "Overweight" rating and a $30.00 price target on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($1.21) per share. Cantor Fitzgerald also issued estimates for Capricor Therapeutics' FY2026 earnings at $1.12 EPS.

CAPR has been the topic of a number of other reports. HC Wainwright reiterated a "buy" rating and issued a $24.00 price objective (down from $77.00) on shares of Capricor Therapeutics in a report on Friday, July 11th. Alliance Global Partners reissued a "buy" rating on shares of Capricor Therapeutics in a research note on Monday, July 14th. Wall Street Zen downgraded Capricor Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Roth Capital reduced their target price on shares of Capricor Therapeutics from $31.00 to $12.00 and set a "buy" rating for the company in a report on Monday, July 14th. Finally, Jones Trading decreased their price objective on Capricor Therapeutics from $40.00 to $29.00 and set a "buy" rating on the stock in a report on Wednesday, June 25th. One analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $22.56.

Capricor Therapeutics Stock Down 3.9%

Shares of NASDAQ:CAPR traded down $0.28 during midday trading on Wednesday, reaching $6.88. 2,087,735 shares of the company were exchanged, compared to its average volume of 2,109,144. The firm has a market cap of $314.28 million, a PE ratio of -4.85 and a beta of 0.82. Capricor Therapeutics has a fifty-two week low of $3.52 and a fifty-two week high of $23.40. The stock has a fifty day simple moving average of $10.29 and a two-hundred day simple moving average of $11.88.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.20). The firm had revenue of $2.73 million during the quarter, compared to analyst estimates of $3.16 million. Capricor Therapeutics had a negative return on equity of 62.42% and a negative net margin of 181.71%. During the same quarter last year, the business posted ($0.31) earnings per share.

Institutional Trading of Capricor Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Summit Investment Advisors Inc. raised its stake in Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock worth $53,000 after buying an additional 1,345 shares during the last quarter. Russell Investments Group Ltd. grew its position in Capricor Therapeutics by 172.8% in the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock worth $64,000 after purchasing an additional 2,947 shares in the last quarter. Virtus ETF Advisers LLC bought a new stake in shares of Capricor Therapeutics during the 4th quarter worth $68,000. AlphaQuest LLC bought a new stake in shares of Capricor Therapeutics in the 4th quarter worth approximately $78,000. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Capricor Therapeutics during the 4th quarter valued at $91,000. 21.68% of the stock is currently owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.